Pharma major Zydus Cadila on Monday said the company has received final approval from the US drug regulator to market Clonidine Hcl injections.
According to the announcement made by the company, the US Food and Drug Administration (USFDA) has given approval “to market Clonidine Hcl injection 0.1 and 0.5 mg/ml, 10 ml.”
Clonidine hydrochloride injection is a centrally-acting analgesic solution for use in continuous epidural infusion devices, which is indicated in combination with opiates for the treatment of severe pain in cancer patients that is not adequately relieved by opioid analgesics alone, the company statement said.
The group now has 90 approvals and has so far filed 216 Abbreviated New Drug Applications (ANDA) since the commencement of the filing process in fiscal 2003-04.